BioSpace News Archive

Mycosis fungoides is the most common type of blood cancer known as cutaneous T-cell lymphoma. Cutaneous T-cell lymphoma occurs when certain T-cells become cancerous. These cancers affect the skin and cause different types of lesions on the skin.

Malabsorption syndrome is a disorder that occurs when a person is incapable to absorb certain nutrients such as proteins, carbohydrates, fats, vitamins, and minerals from the diet.

Food intolerance is an abnormal non-immune response with allergy-like symptoms after ingesting of food. It can result from pharmacological reactions, enzyme deficiencies, or response to toxic or irritant components of food.

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE clinical program evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) presented at the American College of Neuropsychopharmacology (ACNP) Congress taking place December 5-8 in San Juan, Puerto Rico.

SynDevRx, Inc. today announced they will be presenting pre-clinical mechanistic/molecular data with evexomostat (SDX-7320) using the Her2+ xenograft model (BT474) in combination with capivasertib/AZD-5363 during the 2021 San Antonio Breast Cancer Symposium.

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively “Amneal”).

Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers.

Passage Bio, Inc. today announced the expansion of its pipeline and provided a progress update on its three clinical programs.

IGM Biosciences, Inc. today announced a grant agreement with the Bill & Melinda Gates Foundation to fund the design, production, and evaluation of IgM and IgA antibodies for the potential prevention of malaria.

Calyxt, Inc., a plant-based synthetic biotechnology company, announced the completion of a key milestone in its lab-scale BioFactory™ manufacturing system.